TY  - JOUR
TI  - Hematological toxicities of cyclin-dependent kinase 4 and 6 inhibitors in metastatic breast cancer: Single institution experience
AU  - Kutić, Slobodan
AU  - Milović-Kovačević, Marijana
AU  - Novaković, Teodora
AU  - Ćosović, Vojislav
AU  - Purić, Mila
T2  - Serbian Journal of the Medical Chamber
AB  - Introduction: Hematologic toxicity is the most common side effect of CDK4/6 inhibitors (CDK4/6i). Due to the novelty of these drugs, additional data are needed to identify potential predisposing factors for the development of hematologic toxicities. Aim: This study aims to investigate potential predisposing factors for the development of hematological toxicity during the administration of CDK4/6i in the treatment of metastatic breast cancer. Methods: This retrospective descriptive study investigated the application of CDK4/6i in patients with metastatic breast cancer treated at the Breast Department of IORS from 1.1.2021 to 1.6.2024. Results: 128 patients were included in the study; 43% were treated with palbociclib and 57% with ribociclib. The median age was 60 years. Median follow-up was 12 months (range 2-23). Neutropenia was observed in 82.1% of patients and grade 3/4 in 43%. Dose reduction due to repeated grade 3/4 neutropenia was required in 21.1% of subjects. Grade 3/4 anemia and thrombocytopenia were observed in 0.8% and 1.6% of patients. Discontinuation of therapy due to hematological toxicities was necessary in 1.5% of patients. There was no statistically significant difference between the two drugs regarding the incidence of hematological toxicity (p = 0.443). Previous use of chemotherapy in the metastatic phase of the disease was not significantly associated with the frequency of hematological toxicity (p = 0.565). Palliative radiotherapy of bone lesions showed a statistically significant association with the need to reduce the dose of CDK4/6i (p =0.001, r = 0.283). Median progression-free survival (PFS) was not reached, but there was no trend to suggest that CDK4/6i dose reduction affected PFS (p = 0.719) Conclusion: Palliative radiotherapy of bone lesions is associated with more frequent dose reduction of CDK4/6i, but dose reduction of these drugs did not affect the length of survival.
DA  - 2024///
PY  - 2024
DO  - 10.5937/smclk5-52481
VL  - 5
IS  - 3
SP  - 320
EP  - 330
SN  - 2737-9752
UR  - https://www.smj.rs/en/volume-5-no-3/hematological-toxicities-of-cyclin-dependent-kinase-4-and-6-inhibitors-in-metastatic-breast-cancer-single-institution-experience
ER  -